Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:BHST NASDAQ:CLNN NYSE:CPHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.33-2.6%$2.22$1.54▼$5.50$81.42M1.26712,091 shs464,691 shsBHSTBioHarvest Sciences$3.95+7.0%$4.29$3.57▼$12.80$77.50M0.8130,088 shs9,905 shsCLNNClene$6.04-7.1%$5.89$2.28▼$13.50$71.14M0.89363,873 shs262,286 shsCPHIChina Pharma$0.69+29.0%$0.60$0.38▼$2.60$25.86M0.99158,636 shs10.51 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+4.27%+19.39%+51.10%-0.21%+56.03%BHSTBioHarvest Sciences-7.05%-14.66%-14.39%-25.00%-42.70%CLNNClene-10.71%+5.86%+6.38%+47.06%+147.15%CPHIChina Pharma+3.44%+2.85%-12.18%-19.97%-74.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.33-2.6%$2.22$1.54▼$5.50$81.42M1.26712,091 shs464,691 shsBHSTBioHarvest Sciences$3.95+7.0%$4.29$3.57▼$12.80$77.50M0.8130,088 shs9,905 shsCLNNClene$6.04-7.1%$5.89$2.28▼$13.50$71.14M0.89363,873 shs262,286 shsCPHIChina Pharma$0.69+29.0%$0.60$0.38▼$2.60$25.86M0.99158,636 shs10.51 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+4.27%+19.39%+51.10%-0.21%+56.03%BHSTBioHarvest Sciences-7.05%-14.66%-14.39%-25.00%-42.70%CLNNClene-10.71%+5.86%+6.38%+47.06%+147.15%CPHIChina Pharma+3.44%+2.85%-12.18%-19.97%-74.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.25Hold$13.50490.81% UpsideBHSTBioHarvest Sciences 2.00Hold$10.00159.81% UpsideCLNNClene 2.67Moderate Buy$33.25425.77% UpsideCPHIChina Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CPHI, CLNN, ANVS, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/14/2026ANVSAnnovis Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.003/27/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026CLNNClene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.003/12/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.002/19/2026BHSTBioHarvest Sciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/ABHSTBioHarvest Sciences$34.51M2.19N/AN/A$1.30 per share2.96CLNNClene$200K372.42N/AN/A($1.62) per share-3.90CPHIChina Pharma$4.14M3.84N/AN/A$0.70 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$28.85M-$1.40N/AN/AN/AN/A-159.43%-133.49%5/19/2026 (Estimated)BHSTBioHarvest Sciences-$11.14M-$0.61N/AN/AN/A-32.27%-136.42%-27.92%5/14/2026 (Estimated)CLNNClene-$26.17M-$2.60N/AN/AN/A-13,086.50%N/A-135.77%5/13/2026 (Estimated)CPHIChina Pharma-$3.08M-$0.75N/AN/AN/A-85.56%-63.93%-31.42%N/ALatest CPHI, CLNN, ANVS, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026ANVSAnnovis Bio-$0.3950N/AN/AN/AN/AN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13N/AN/AN/A$8.50 millionN/A5/13/2026Q1 2026CLNNClene-$0.6362N/AN/AN/A$0.06 millionN/A4/1/2026Q4 2025BHSTBioHarvest Sciences-$0.11-$0.10+$0.01-$0.10$9.24 million$9.07 million3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/A3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A5.805.80BHSTBioHarvest Sciences0.103.973.38CLNNCleneN/A0.830.83CPHIChina Pharma0.220.790.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%BHSTBioHarvest SciencesN/ACLNNClene23.28%CPHIChina PharmaN/AInsider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%BHSTBioHarvest SciencesN/ACLNNClene28.30%CPHIChina Pharma6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACLNNClene10011.78 million8.45 millionNo DataCPHIChina Pharma25040.52 million15.92 millionNot OptionableCPHI, CLNN, ANVS, and BHST HeadlinesRecent News About These CompaniesChina Pharma (NYSE:CPHI) Trading Down 4.5% - Should You Sell?May 7, 2026 | americanbankingnews.comChina Pharma Delays 10-K but Shows Narrowing LossesApril 27, 2026 | theglobeandmail.comInside CPHI Americas 2026 AgendaApril 16, 2026 | pharmtech.comPIs China Pharma’s New Cash Cow Or A Policy Risk?March 12, 2026 | forbes.com[PRNewswire] The largest pharma show in Asia makes its returnMarch 2, 2026 | en.yna.co.krEThe largest pharma show in Asia makes its return to Shanghai this June 2026March 2, 2026 | manilatimes.netMChina’s Drug Industry Moves From ‘Follower To Leader’February 18, 2026 | forbes.comCPHI & PMEC China to take place from June 16 to 18 at ShanghaiFebruary 11, 2026 | pharmabiz.comPChina Pharma stockholders approve reverse split, governance changesJanuary 20, 2026 | theglobeandmail.comMagazine: Biopharma’s 2025 M&A boomDecember 23, 2025 | finance.yahoo.comChina Pharma (NYSE:CPHI) Stock Price Down 10.2% – Should You Sell?December 12, 2025 | defenseworld.netDCPHI & PMEC India Strengthens India’s Role As A Global Pharma Powerhouse: Yogesh MudrasNovember 27, 2025 | businessworld.inB'Heart of Pharma' Returns: CPHI & PMEC India 2025 to Drive Innovation and Strategic GrowthNovember 17, 2025 | thehansindia.comTThree-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investorsNovember 15, 2025 | msn.comPharma Event: CPHI & PMEC India 2025November 13, 2025 | money.rediff.comMCPhI Frankfurt 2025: Uzbekistan participates in pharmaceutical exhibitionOctober 29, 2025 | app.com.pkATOPPAN to Join CPHI Frankfurt 2025October 21, 2025 | news.marketersmedia.comNKnowledge-based companies to attend CIIE in China, CPHI in IndiaSeptember 30, 2025 | tehrantimes.comTCPHI Frankfurt Returns to Germany October 28-30September 11, 2025 | contractpharma.comCPharma Spent More Than $48B in China in H1, Eclipsing Total 2024 HaulAugust 27, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPHI, CLNN, ANVS, and BHST Company DescriptionsAnnovis Bio NYSE:ANVS$2.33 -0.06 (-2.55%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.BioHarvest Sciences NASDAQ:BHST$3.95 +0.26 (+7.05%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Clene NASDAQ:CLNN$6.04 -0.46 (-7.08%) As of 01:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.China Pharma NYSE:CPHI$0.69 +0.15 (+28.98%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas On Holdings Sets Up for Marathon Rally: New Highs Are Coming Shake Shack Stock Gets Shaken After Earnings Miss Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? MP Materials Is Quietly Building a Rare Earth Powerhouse The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000 Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
